• KaliVir Immunotherapeutics

  Participated · Series A · Aug 2026

  KaliVir develops next-generation oncolytic immunotherapies using its proprietary Vaccinia Enhanced Template (VET) platform to integrate multiple genetic modifications into viral backbones for systemic delivery and targeted expression of therapeutic transgenes within tumors. Its lead candidate, VET3-TGI, is being evaluated as both monotherapy and in combination with atezolizumab in the STEALTH-001 Phase 1/1b trial for patients with advanced solid tumors. The company plans to use the newly raised funds to support ongoing clinical development and patient enrollment in STEALTH-001 and for general corporate purposes. KaliVir is led by CEO Helena Chaye, PhD, JD, and is based in Pittsburgh, PA. Financially, the company has now raised a total of $25M following the $14M Series A extension.

• Linq

  Participated · Series A · Jul 2026

  LinqAlpha builds a platform that lets institutional investors deploy specialized AI agents that synthesize thousands of signals and learn each user's unique investment framework to surface differentiated insights. The company was founded by Jacob Choi, Subeen Pang, Jin Kim, and Hojun Choi and brings together former Goldman Sachs analysts and MIT computer science PhDs. Since launch, LinqAlpha has been adopted by over 70 financial institutions across the U.S., Europe, and Asia, including sell-side teams at investment banks and buy-side clients such as Causeway Capital Management and Schonfeld Strategic Advisors. Collectively, its buy-side clients manage more than $5 trillion in assets. LinqAlpha is headquartered in New York and plans to use its Series A proceeds to expand its global team, deepen dataset integrations, and accelerate deployment across equities, macro, credit, and multi-asset strategies. The company frames its product as an "Alpha Intelligence Layer" designed to help institutional teams synthesize fast, interconnected public-market signals into actionable judgment.

• CarbonSix

  Participated · Series A · Jul 2026

  CarbonSix develops deployment-ready robotic intelligence software and hardware, including robotic hands and manipulators, for manufacturing applications. The company emphasizes field reliability and immediate integration into production lines, and reports commercial contracts and scaling revenue as evidence of market traction. Its core business model is a proprietary "data flywheel" where tool usage in factories generates task-specific data that improves its AI models over time. The founding team includes executives and researchers with prior exits and advanced academic credentials, supporting technical and commercial credibility. CarbonSix plans to use its Series A proceeds to hire talent, scale infrastructure, and expand into global markets.

• Asteromorph

  Participated · Seed · May 2026

  Asteromorph develops a foundation model, Spacer, that it says combines a base LLM with deep domain knowledge and multi-step reasoning to autonomously generate research ideas and scientific hypotheses in biology and chemistry. Its flagship initiative, the "Library Project," aims to run the autonomous system at scale to uncover fundamental mechanisms of life and compile findings into a structured database. The company emphasizes autonomous hypothesis generation and end-to-end scientific workflows rather than solely assisting human researchers. Leadership includes CEO Lee Min-hyung, who entered advanced research training early, and a core team of young researchers from top Korean STEM programs. Financially, Asteromorph has raised a $31.4M seed round and previously raised approximately ₩5 billion. The company faces the challenge of validating model-generated discoveries through rigorous experimental work at scale.

• BreezeBio

  Participated · Series B · Feb 2026

  BreezeBio, formerly GenEdit, engineers polymer-based NanoGalaxy nanoparticles that deliver genetic payloads such as mRNA with cell-type precision across immune, cardiac, pulmonary and central nervous system tissues. The company has shifted from being solely a delivery-technology provider to building a therapeutic pipeline concentrated on autoimmune disease and oncology. Its lead candidate, BRZ-101, delivers autoantigen-encoding mRNA and tolerogenic co-factors to antigen-presenting cells to induce antigen-specific regulatory T cells and aims to restore immune tolerance in type 1 diabetes; the program is now entering IND-enabling studies after positive preclinical results in mice and non-human primates. BreezeBio is also extending NanoGalaxy with ligand conjugation to reach T cells and enable in vivo CAR-T therapies. Beyond internal programs, the firm maintains a multi-year collaboration and licensing agreement with Genentech that has already produced an initial milestone payment. The recent financing strengthens its balance sheet, allowing continued platform expansion and clinical advancement of its pipeline.

No current team members are available.